AstraZeneca 'not selling EU doses to other countries' – CEO

AstraZeneca 'not selling EU doses to other countries' – CEO

Tuesday, January 26, 2021

Print this page Email A Friend!

PARIS,France(AFP)— AstraZeneca's CEO insisted Tuesday that the company was not selling vaccines ordered by the European Union to other countries at a profit, after delayed orders sparked fury from EU leaders.

The British-Swedish drugs firm admitted last week that it would not meet its contractual delivery commitments to the EU because of "reduced yields" in its European supply chain.

That prompted European Health Commissioner Stella Kyriakides to announce that the EU plans to start tracking vaccine shipments exported to non-member countries -- a sign of growing distrust.

"The European Union wants to know exactly which doses have been produced where by AstraZeneca so far, and if or to whom they have been delivered," she said Monday.

AstraZeneca's CEO Pascal Soriot sought to calm the situation on Tuesday, acknowledging that European governments were growing "aggravated or emotional" due to repeated stumbling blocks in their vaccine rollouts.

"Our team is working 24/7 to fix the very much issues of production of the vaccine itself," he told the LENA European newspaper alliance.

He stressed: "We're certainly not taking vaccines away from the Europeans to sell it somewhere else at the profit."

The company, which teamed up with Oxford University to develop its vaccine, has pledged not to make a profit on sales of the jab during the pandemic.

The company is working with Oxford to develop a vaccine that specifically targets a more infectious South African strain of COVID-19, Soriot said.

- UK 'had time to fix glitches' -

Europe's AstraZeneca woes came a week after US group Pfizer said it was also cutting early delivery volumes of its vaccine produced with German firm BioNTech.

Those two announcements have risked up-ending the EU's vaccination programmes while heaping pressure on the European Commission, which took on the task of negotiating vaccine orders on behalf of all 27 member states.

Soriot noted that recently-departed EU member Britain -- which said Tuesday it was confident of receiving all its vaccine doses -- had started its rollout three months earlier.

"So with the UK we havehad an extra three months to fix all the glitches we experienced," he said.

The Oxford-AstraZeneca vaccine is still awaiting regulatory approval in the EU, with a decision from the European Medicines Agency due Friday.

The firm said last year that it had agreed with the European Commission to supply up to 400 million doses to the EU.

"As soon as we get an approval by EMA, in the next few days, we will be shipping at least three million doses immediately to Europe," Soriot said.

"The target is to deliver 17 million doses by February."

Europe is on track to receive 17 percent of AstraZeneca's global production in February "for a population that is five per cent of the world population", he noted.

The AstraZeneca vaccine is cheaper than that produced by rivals such as Moderna and Pfizer, and is also easier to stock since it does not need to be kept at ultra-low temperatures.

Now you can read the Jamaica Observer ePaper anytime, anywhere. The Jamaica Observer ePaper is available to you at home or at work, and is the same edition as the printed copy available at




1. We welcome reader comments on the top stories of the day. Some comments may be republished on the website or in the newspaper � email addresses will not be published.

2. Please understand that comments are moderated and it is not always possible to publish all that have been submitted. We will, however, try to publish comments that are representative of all received.

3. We ask that comments are civil and free of libellous or hateful material. Also please stick to the topic under discussion.

4. Please do not write in block capitals since this makes your comment hard to read.

5. Please don't use the comments to advertise. However, our advertising department can be more than accommodating if emailed:

6. If readers wish to report offensive comments, suggest a correction or share a story then please email:

7. Lastly, read our Terms and Conditions and Privacy Policy

comments powered by Disqus



Today's Cartoon

Click image to view full size editorial cartoon